KVA 12.1 a novel fully human anti-VISTA antibody clinical trial design in monotherapy and in combination with an anti-PD1 antibody
Thierry Guillaudeux, Chief Scientific Officer Society for Immunotherapy of Cancer (SITC) 2021 | November, 2021
Kineta Presents Preclinical Data on its New CD27 Program at the AACR Conference on Tumor Immunology and Immunotherapy
Kineta Presents Preclinical Data on its New CD27 Program at the AACR Conference on Tumor Immunology and Immunotherapy Kineta expands the company’s immuno-oncology pipeline with the addition of a new ...
A promising cancer immunotherapy target: Novel agonistic human antibody against the human T-cell costimulatory receptor CD27
Thierry Guillaudeux, Phd, Chief Scientific Officer American Association for Cancer Research (AACR) Virtual Special Conference on Tumor Immunology and Immunotherapy | October 5-6, 2021
Kineta Announces Poster Presentation at the 2021 American Association for Cancer Research Conference on Tumor Immunology and Immunotherapy
Kineta Announces Poster Presentation at the 2021 American Association for Cancer Research Conference on Tumor Immunology and Immunotherapy Seattle, WA — (September 28, 2021) Kineta, Inc., a clinical ...
Kineta Announces Participation at H.C. Wainwright 23rd Annual Global Investment Conference
Kineta Announces Participation at H.C. Wainwright 23rd Annual Global Investment Conference Seattle, WA — (August 30, 2021) Kineta, Inc., a clinical stage biotechnology company focused on the developm ...
Kineta Announces Patent Issuance of U.S. Patent for Composition of Matter of KCP506
Kineta Announces Patent Issuance for U.S. Patent Covering Composition of Matter of KCP506, a Novel Non-opioid Therapy for Chronic Pain Seattle, WA -- (August 10, 2021) Kineta Inc, through its subsidi ...
Research Associate, Immuno-oncology
Research Associate, Immuno-oncology Reports to: SVP, Immuno-oncology Job Description The Research Associate is expected to effectively support the completion of key studies in the preclinical devel ...
Scientist, Immuno-oncology
Scientist, Immune-oncology Reports to: VP of Immuno-oncology Job Description The Scientist will support the preclinical development of new immuno-oncology drugs for the treatment of diverse solid ...
Kineta Announces Successful Completion of Pre-IND Meeting with the FDA for KVA12.1
Kineta Announces Successful Completion of Pre-IND Meeting with the FDA for KVA12.1 Phase 1/2 clinical studies of the company’s anti-VISTA antibody to commence in mid-2022 Seattle, WA — (July 27, 202 ...
Kineta Announces First Participant Dosed in Phase 1 Multiple Ascending Dose Clinical Trial of KCP506
Kineta Announces First Participant Dosed in Phase 1 Multiple Ascending Dose Clinical Trial of KCP506 Seattle, WA — (July 14, 2021) Kineta Inc, through its subsidiary Kineta Chronic Pain LLC, announce ...